159 related articles for article (PubMed ID: 3203647)
1. Bone lead, hypertension, and lead nephropathy.
Wedeen RP
Environ Health Perspect; 1988 Jun; 78():57-60. PubMed ID: 3203647
[TBL] [Abstract][Full Text] [Related]
2. Reducing bone lead content by chelation treatment in chronic lead poisoning: an in vivo X-ray fluorescence and bone biopsy study.
Batuman V; Wedeen RP; Bogden JD; Balestra DJ; Jones K; Schidlovsky G
Environ Res; 1989 Feb; 48(1):70-5. PubMed ID: 2492468
[TBL] [Abstract][Full Text] [Related]
3. Bone lead in dialysis patients.
Van de Vyver FL; D'Haese PC; Visser WJ; Elseviers MM; Knippenberg LJ; Lamberts LV; Wedeen RP; De Broe ME
Kidney Int; 1988 Feb; 33(2):601-7. PubMed ID: 3129611
[TBL] [Abstract][Full Text] [Related]
4. Renal effects of environmental and occupational lead exposure.
Loghman-Adham M
Environ Health Perspect; 1997 Sep; 105(9):928-38. PubMed ID: 9300927
[TBL] [Abstract][Full Text] [Related]
5. Use of the CaNa2 EDTA Pb-mobilization test to detect occult lead nephropathy.
Wedeen RP
Uremia Invest; 1985-1986; 9(2):127-30. PubMed ID: 3939486
[TBL] [Abstract][Full Text] [Related]
6. The role of lead in renal failure.
Wedeen RP
Clin Exp Dial Apheresis; 1982; 6(2-3):113-46. PubMed ID: 6758998
[TBL] [Abstract][Full Text] [Related]
7. Chronic renal failure with gout: a marker of chronic lead poisoning.
Craswell PW; Price J; Boyle PD; Heazlewood VJ; Baddeley H; Lloyd HM; Thomas BJ; Thomas BW
Kidney Int; 1984 Sep; 26(3):319-23. PubMed ID: 6439940
[TBL] [Abstract][Full Text] [Related]
8. Strategies for epidemiologic studies of lead in bone in occupationally exposed populations.
Landrigan PJ
Environ Health Perspect; 1991 Feb; 91():81-6. PubMed ID: 2040253
[TBL] [Abstract][Full Text] [Related]
9. Contribution of lead to hypertension with renal impairment.
Batuman V; Landy E; Maesaka JK; Wedeen RP
N Engl J Med; 1983 Jul; 309(1):17-21. PubMed ID: 6406892
[TBL] [Abstract][Full Text] [Related]
10. Bone lead and the diagnosis of lead nephropathy.
Wedeen RP; Van de Vyver FL; D'Haese PC; Visser WJ; Elseviers MM; Knippenberg LJ; Lamberts LV; De Broe ME; Batuman V; Schidlovsky G
Contrib Nephrol; 1988; 64():102-8. PubMed ID: 3141113
[No Abstract] [Full Text] [Related]
11. Lead nephropathy, gout, and hypertension.
Batuman V
Am J Med Sci; 1993 Apr; 305(4):241-7. PubMed ID: 8475950
[TBL] [Abstract][Full Text] [Related]
12. In vivo bone lead measurements: a rapid monitoring method for cumulative lead exposure.
Wielopolski L; Ellis KJ; Vaswani AN; Cohn SH; Greenberg A; Puschett JB; Parkinson DK; Fetterolf DE; Landrigan PJ
Am J Ind Med; 1986; 9(3):221-6. PubMed ID: 3963004
[TBL] [Abstract][Full Text] [Related]
13. Lead and the kidney: nephropathy, hypertension, and gout.
Perazella MA
Conn Med; 1996 Sep; 60(9):521-6. PubMed ID: 8908777
[TBL] [Abstract][Full Text] [Related]
14. Lead in vertebral bone biopsies from active and retired lead workers.
Schütz A; Skerfving S; Christoffersson JO; Ahlgren L; Mattson S
Arch Environ Health; 1987; 42(6):340-6. PubMed ID: 3439810
[TBL] [Abstract][Full Text] [Related]
15. Bone lead and blood lead levels in relation to baseline blood pressure and the prospective development of hypertension: the Normative Aging Study.
Cheng Y; Schwartz J; Sparrow D; Aro A; Weiss ST; Hu H
Am J Epidemiol; 2001 Jan; 153(2):164-71. PubMed ID: 11159162
[TBL] [Abstract][Full Text] [Related]
16. [Determination of lead in hydride form in bone biopsies of patients with long past lead poisoning].
Kijewski H; Lowitz HD
Arch Toxicol; 1982 Sep; 50(3-4):301-11. PubMed ID: 7149993
[TBL] [Abstract][Full Text] [Related]
17. Chronic lead nephropathy in Queensland: alternative methods of diagnosis.
Craswell PW; Price J; Boyle PD; Heazlewood VJ; Baddeley H; Lloyd HM; Thomas BJ; Thomas BW; Williams GM
Aust N Z J Med; 1986 Feb; 16(1):11-9. PubMed ID: 3085647
[TBL] [Abstract][Full Text] [Related]
18. Body burdens of lead in hypertensive nephropathy.
Osterloh JD; Selby JV; Bernard BP; Becker CE; Menke DJ; Tepper E; Ordonez JD; Behrens B
Arch Environ Health; 1989; 44(5):304-10. PubMed ID: 2510613
[TBL] [Abstract][Full Text] [Related]
19. Clinical application of in vivo tibial K-XRF for monitoring lead stores.
Wedeen RP; Ty A; Udasin I; Favata EA; Jones KW
Arch Environ Health; 1995; 50(5):355-61. PubMed ID: 7574889
[TBL] [Abstract][Full Text] [Related]
20. X-ray fluorescence: issues surrounding the application of a new tool for measuring burden of lead.
Hu H; Milder FL; Burger DE
Environ Res; 1989 Aug; 49(2):295-317. PubMed ID: 2753011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
